Home > Insider Trading > Filing (0000950170-24-010968)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1593899	Atea Pharmaceuticals Inc.	AVIR	Pharmaceutical Preparations (2834)	460574869

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1829630	John Vavricka	225 Franklin Street Suite 2100 Boston MA 02110	Chief Commercial Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-01-31	33,334	$0.00	33,334	No	4	M	Direct
Common Stock	Disposition	2024-02-01	11,819	$3.84	21,515	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2024-01-31	33,334	$0.00	33,334	$0.00
Common Stock	Stock Option (Right to Buy)	Acquisiton	2024-01-31	132,800	$0.00	132,800	$4.16

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
66,666			No	4	M	Direct
132,800		2034-01-30	No	4	A	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	82,508	Indirect	Held by John Vavricka as the Trustee of the John F. Vavricka Deed of Trust

Footnotes

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
Shares were sold solely to cover taxes upon the vesting of restricted stock units pursuant to a standing Rule 10b5-1 instruction dated March 25, 2022.
The original grant of 100,000 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.
The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2024 such that the option is fully vested on January 31, 2028.